Fast Market Research

"Liver Cancer - Pipeline Review, H2 2016" Now Available at Fast Market Research

Fast Market Research announces the availability of the new Global Markets Direct report, "Liver Cancer - Pipeline Review, H2 2016", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 02/20/2017 -- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cancer - Pipeline Review, H2 2016, provides an overview of the Liver Cancer (Oncology) pipeline landscape.

Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Get More Details on this Report and a Full Table of Contents at Liver Cancer - Pipeline Review, H2 2016

The Liver Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 76, 52, 8, 121 and 19 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 15, 8, 1, 30 and 3 molecules, respectively.

Liver Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cancer (Oncology).

-The pipeline guide reviews pipeline therapeutics for Liver Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Liver Cancer (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Liver Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cancer (Oncology)

Reasons to Get this Report

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Liver Cancer (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Liver Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Companies Mentioned in this Report: 4SC AG, AB Science SA, Acceleron Pharma Inc, ACROVIS Pharma AG, Adaptimmune Therapeutics Plc, Aduro BioTech Inc, Advenchen Laboratories LLC, Alfact Innovation, Alissa Pharma, Alnylam Pharmaceuticals Inc, American Gene Technologies International Inc, Amgen Inc, AndroScience Corp, APAvadis Biotechnologies Srl, ArQule Inc, Array BioPharma Inc, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, AVEO Pharmaceuticals Inc, Bayer AG, BeiGene Ltd, Beijing Kawin Technology Share-Holding Co Ltd, Betta Pharmaceuticals Co Ltd, Bio-Cancer Treatment International Ltd, BioCancell Ltd, Biogazelle NV, Biomics Biotechnologies Co Ltd, Bioneer Corp, BioStar Pharmaceuticals Inc, BLR Bio LLC, Blueprint Medicines Corp, Boehringer Ingelheim GmbH, Boryung Pharmaceutical Co Ltd, Boston Biomedical Inc, Bristol-Myers Squibb Company, Can-Fite BioPharma Ltd, CASI Pharmaceuticals Inc, CBT Pharmaceuticals Inc, CCRP Therapeutics GmbH, Celgene Corp, Celldex Therapeutics Inc, Celprogen Inc, Celsion Corp, China Medical System Holdings Ltd, Chiome Bioscience Inc, Chipscreen Biosciences Ltd, Chroma Therapeutics Ltd, Chugai Pharmaceutical Co Ltd, CohBar Inc, CZ BioMed Corp, Daiichi Sankyo Company Ltd, Delcath Systems Inc, Dicerna Pharmaceuticals Inc, Double Bond Pharmaceutical International AB, Eisai Co Ltd, Eli Lilly and Company, Endocyte Inc, Epeius Biotechnologies Corp, eTheRNA Immunotherapies NV, Eureka Therapeutics Inc, Exelixis Inc, F. Hoffmann-La Roche Ltd, Faron Pharmaceuticals Oy, Formosa Laboratories Inc, Galaxy Biotech LLC, Genelux Corp, Genoscience Pharma, Genosco Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Golden Biotechnology Corp, Green Cross Cell Corp, Green Cross Corp, H3 Biomedicine Inc, HanAll Biopharma Co Ltd, HEC Pharm Co Ltd, HitGen LTD, Horizon Pharma Plc, Immune Therapeutics Inc, Immunicum AB, Immunitor Inc, Immunomedics Inc, Immunophotonics Inc, Immunovative Therapies Ltd, IMPACT Therapeutics Inc, In-Cell-Art SAS, Incanthera Ltd, Inovio Pharmaceuticals Inc, Inspyr Therapeutics Inc, InteRNA Technologies BV, Intezyne Technologies Inc, Jasco Pharmaceuticals LLC, Jenrin Discovery Inc, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, JW Pharmaceutical Corp, KAHR medical Ltd, Karcinolys SAS, Keystone Nano Inc, Kite Pharma Inc, Komipharm International Co Ltd, Kowa Company Ltd, Les Laboratoires Servier SAS, Lidds AB, Ligand Pharmaceuticals Inc, Lixte Biotechnology Holdings Inc, Lytix Biopharma AS, MaxCyte Inc, MedImmune LLC, Medivation Inc, Medivir AB, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Midatech Pharma Plc, Millennium Pharmaceuticals Inc, Mina Therapeutics Ltd, Molecular Partners AG, MultiCell Technologies Inc, NormOxys Inc, Northwest Biotherapeutics Inc, Novartis AG, NovaTarg Therapeutics Inc, Nymox Pharmaceutical Corp, Omeros Corp, Omnitura Therapeutics Inc, Oncolys BioPharma Inc, OncoMed Pharmaceuticals Inc, OncoTherapy Science Inc, Oneness Biotech Co Ltd, Ono Pharmaceutical Co Ltd, Onxeo SA, OPKO Health Inc, Oribase Pharma, OSE Immunotherapeutics, Otsuka Holdings Co Ltd, Panacea Pharmaceuticals Inc, Peptinov SAS, PepVax Inc, Peregrine Pharmaceuticals Inc, Pfizer Inc, Pharma Mar SA, PharmAbcine Inc, PharmaEssentia Corp, Phosplatin Therapeutics LLC, ProMetic Life Sciences Inc, Provecs Medical GmbH, Provectus Biopharmaceuticals Inc, RedHill Biopharma Ltd, Regen BioPharma Inc, Regulus Therapeutics Inc, Rigontec GmbH, Samumed LLC, Saronic Biotechnology Inc, Savoy Pharmaceuticals Inc, Shenogen Pharma Group Ltd, Shenzen SiBiono GeneTech Co Ltd, Silence Therapeutics Plc, Sillajen Biotherapeutics, Simcere Pharmaceutical Group, Somantix BV, Sorrento Therapeutics Inc, Synovo GmbH, TaiRx Inc, Taiwan Liposome Company Ltd, Tara Immuno-Oncology Therapeutics LLC, Targetome SA, TC BioPharm Ltd, Tessa Therapeutics Pte Ltd, Therapure Biopharma Inc, Theravectys SA, Threshold Pharmaceuticals Inc, Tiziana Life Sciences Plc, TRACON Pharmaceuticals Inc, Transgene Biotek Ltd, Tumorend LLC, UbiVac LLC, VasGene Therapeutics Inc, Vaxon Biotech, Vect-Horus SAS, Verlyx Pharma Inc, VG Life Sciences Inc, Vicus Therapeutics LLC, Virttu Biologics Ltd

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:
-Metastatic Colorectal Cancer - Pipeline Review, H2 2016
-Metastatic Breast Cancer - Pipeline Review, H2 2016
-Small-Cell Lung Cancer - Pipeline Review, H2 2016
-Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016
-Head And Neck Cancer - Pipeline Review, H2 2016